

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	1	of	13	Attorney Docket Number	E072 1050.1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-20070254300	11-01-2007	Cimbora et al.	
	2	US-20070225209-A1	09-27-2007	Roch et al.	
	3	US-6,897,066-B1	05-24-2005	Harrington	
	4	US-20040226056-A1	11-11-2004	Roch et al.	
	5	US-20040058400-A1	03-25-2004	Holliger et al.	
	6	US-20030148937-A1	08-07-2003	Mansfield et al.	
	7	US-20030121063-A1	06-26-2003	Kazazian et al.	
	8	US-20070270360-A1	11-22-2007	McSwiggen et al.	
	9	US-20070203333-A1	08-30-2007	McSwiggen et al.	
	10	US-20060217332-A1	09-28-2006	Vargeese et al.	
	11	US-20050233998-A1	10-20-2005	Jadhav et al.	
	12	US-20050222066-A1	10-06-2005	Richards et al.	
	13	US-20050171039-A1	08-04-2005	McSwiggen et al.	
	14	US-20050159381-A1	07-21-2005	McSwiggen et al.	
	15	US-20050148530-A1	07-07-2005	McSwiggen et al.	
	16	US-20050124567-A1	06-09-2005	McSwiggen et al.	
	17	US-20050075304-A1	04-07-2005	McSwiggen et al.	
	18	US-20010007025-A1	07-05-2001	Bennett et al.	
	19	US-6,214,986-B1	04-10-2001	Bennett et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	20	WO-2005045038-a2	05-19-2005	Sirna Therapeutics Inc.		
	21	WO-2005028649	03-31-2005	Sirna Therapeutics Inc.		
	22	WO-2004092383	10-28-2004	Sirna Therapeutics, Inc.		
	23	WO-03070972	08-28-2003	Ribozyme Pharmaceuticals, Inc.		
	24	WO-03070910	08-28-2003	Ribozyme Pharmaceuticals, Inc.		
	25	WO-0020432	04-13-2000	ISIS Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	2	of	13	Attorney Docket Number	E072 1050.1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	26	WO-0238738	05-16-2002	Cold Spring Harbor Lav		<input type="checkbox"/>
	27	WO-9410323	05-11-1994	IMP Cancer Res Tech		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	3	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	28	GRAHAM et al., "Alternative Splicing of a Human α -Tropomyosin Muscle-Specific Exon: Identification of Determining Sequences," Molecular and Cellular Biology, Sept. 1992, Vol. 12, No. 9, pgs. 3872-3882		
	29	WATAKABE et al., "The Role of Exon Sequences in Splice Site Selection," Genes Dev., 1993, Vol. 7, pgs. 407-418		
	30	LIU et al., "Identification of Functional Exonic Splicing Enhancer Motifs Recognized by Individual SR proteins," Genes & Development, 1998, Vol. 12, pgs. 1998-2012		
	31	TACKE et al., "The Human Splicing Factors ASF/SF2 and SC35 Posses Distinct, Functionally Significant RNA Binding Specificities," The EMBO Journal, 1995, Vol. 14, No. 14, pgs. 3540-3551		
	32	CARTEGNI et al., "Listening to Silence and Understanding Nonsense: Exonic Mutations that Affect Splicing," Nat. Rev. Genet., April 2002, Vol. 3, pgs. 285-298		
	33	COOPER ET AL., "The Regulation of Splice-Site Selection, and Its Role in Human Disease," Am. J. Hum. Genet., 1997, Vol. 61, pgs. 259-266		
	34	ZHANG et al., "Exon Inclusion is Dependent on Predictable Exonic Splicing Enhancers," Molecular & Cellular Biology, August 2005, Vol. 25, No. 16, pgs. 7323-7332		
	35	ZHANG et al., "Computational Definition of Sequence Motifs Governing Constitutive Exon Splicing," Genes & Development, 2004, Vol. 18, pgs. 1241-1250		
	36	SMITH et al., "An Increased Specificity Score Matrix of the Prediction of SF2/ASF-Specific Exonic Splicing Enhancers," Human Molecular Genetics, 2006, Vol. 15, No. 16, pgs. 2490-2508		
	37	SANFORD et al., "Identification of Nuclear and Cytoplasmic mRNA Targets for the Splicing Protein SF2/ASF," PLoS ONE, October 2008, Vol. 3, Issue 3, pgs. 1-10		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	4	of	13	Attorney Docket Number	E072 1050.1
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	38	YUEN et al., "Phase I Study of an Antisense Oligonucleotide to Protein Kinase C- α (ISIS 3521/CGP 64128A1) in Patients with Cancer ² ," Clinical Cancer Research, November 1999, Vol. 5, pgs. 3357-3363			
	39	"Antisense' Cancer Treatment Looks Safe, Promising," Isis Pharmaceuticals, http://med.stanford.edu/news_releases/1997/mayreleases/antisense.html			
	40	"Hybridon Begins Clinical Trial of First Advanced Antisense Compound; GEM132 to Target Human Cytomegalovirus," PR Newswire, 1996; http://www.aegis.com/news/pr/1996/PR960817.html			
	41	"Enzo Biochem Says Data Shows Significant Progress in Human HIV Gene Medicine Trial," Business Wire, June 2, 2000. http://www.aegis.com/news/bw/2000/BW000602.html			
	42	AVI BioPharma Announces Successful Clinical Trial of AVI-4658 for Treatment of Duchenne Muscular Dystrophy by Exon Skipping, AVI BioPharma, 2009			
	43	GRAHAM et al., "Towards a Therapeutic Inhibition of Dystrophin Exon 23 Splicing in <i>mdx</i> Mouse Muscle Induced by Antisense Oligoribonucleotides (Splicomers): Target Sequence Optimisation Using Oligonucleotide Arrays," J. Gene Med, 2004, Vol. 6, pgs. 1149-1158			
	44	DEUTEKOM et al., "Local Dystrophin Restoration with Antisense Oligonucleotide PRO051," The New England Journal of Medicine, December 27, 2007, Vol. 357, No. 26, pgs. 2677-2686			
	45	PENNISI, E. et al., "Hopping to a Better Protein," Science, December 5, 2008, Vol. 322, pgs. 1454-1455			
	46	WILTON et al., "Exon Skipping and Duchenne Muscular Dystrophy: Hope, Hype and How Feasible?," Neurology India, July-September 2008, Vol. 56, Issue 3, pgs. 254-262			
	47	SUSSMAN et al., "Antisense Treatment for Myasthenia Gravis Experience with Monarsen," Ann. N.Y. Acad. Sci., 2008, Vol. 1132, pgs. 283-290			
	48	BAUMAN, "Therapeutic Potential of Splice-Switching Oligonucleotides," Oligonucleotides, 2009 Mar, Vol. 19, No. 1, pgs. 1-14			
	49	SKORDIS et al., "Bifunctional Antisense Oligonucleotides Provide a Trans-Acting Splicing Enhancer that Stimulates SMN2 Gene Expression in Patient Fibroblast," PNAS, April 1, 2003, Vol. 100, No. 7, pgs. 4114-4119			
	50	MEYER et al., "Rescue of a Severe Mouse Model for Spinal Muscular Atrophy by U7 snRNA-mediated Splicing Modulation," Human Molecular Genetics, 200-9, Vol. 18, No. 3, pgs. 546-555			
	51	MARQUIS et al., "Spinal Muscular Atrophy: SMN2 Pre m-RNA Splicing Corrected by a U7 snRNA Derivative Carrying a Splicing Enhancer Sequence," Molecular Therapy, August 2007, Vol. 15, No. 8, pgs. 1479-1486			
	52	KHOO et al., "Putting Some Spine Into Alternative Splicing," Trends in Biotechnology, August 2003, Vol. 21, No. 8, pgs. 328-330			
	53	SCOTT GOTTLIEB, "The Splice of Life," Background, May 2003, pgs. 1-4			
	54	SIERAKOWSKA et al., "Repair of Thalassemic Human β -Globin mRNA in mammalian Cells by Antisense Oligonucleotides," Proc. Natl. Acad. Sci., November 1996, Vol. 93, pgs. 12840-12844			
	55	TABITHA POWLEDGE, "Exploring the Alternatives," Genome Biology, September 30, 2003,			
	56	MARKER et al., "Experimental RNomics: Identification of 140 Candidates for Small Non-Messenger RNAs in the Plant <i>Arabidopsis Thaliana</i> ," Current Biology, December 10, 2002, Vol. 12, pgs. 2002-2013			
	57	AST et al., "Sequences Upstream of the Branch Site are Required to Form Helix II Between			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		U2 and U6 SnRNA in a Trans-splicing Reaction," Nucleic Acids Research, 2001, Vol. 29, No. 8, pgs. 1741-1749	
	58	AMARASINGHE et al., "An in Vitro-selected RNA-Binding Site for the KH Domain Protein PSI Acts as a Splicing Inhibitor Element," RNA, 2001, Vol. 7, pgs. 1239-1253	
	59	WISTOW et al., "Expressed Sequence Tag Analysis of Human RPE/Choroid for the NEIBank Project: Over 6000 Non-Redundant Transcripts, Novel Genes and Splice Variants," Molecular Vision, 2002, Vol. 8, pgs. 205-20	
	60	HOCKING et al., "Domain-Specific Mutations in Sequestosome 1 (SQSTM1) Cause Familial and Sporadic Paget's Disease," Human Molecular Genetics, 2002, Vol. 11, No. 2, pgs. 2735-2739	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	5	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	61	AGRAWAL et al., "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation," Tetrahedron Letters, 1987, Vol. 28, No. 31, pgs. 3539-3542		
	62	AGRAWAL et al., "Efficient Synthesis of Oligoribonucleotide and its Phosphorothioate Analogue Using H-Phosphonate Approach," Tetrahedron Letters, 1990, Vol. 31, No. 52, pgs. 7541-7544		
	63	AGRAWAL et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus," Proc Natl Acad Sci USA, Oct. 1998, Vol. 85, pgs. 7079-7083		
	64	AGRAWAL et al., "Inhibition of Human Immunodeficiency Virus In Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and their Phosphorothioate Analogues," Proc. Natl. Acad. Sci USA, October 1989, Vol. 86, pgs. 7790-7794		
	65	AGRAWAL et al., "Site-Specific Excision from RNA by RNase H and Mixed-Phosphate-Backbone Oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA, February 1990, Vol. 87, pgs. 1401-1405		
	66	AGRAWAL et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in mice," Proc. Natl. Acad. Sci. USA, September 1, 1990, Vol. 88, pgs. 7595-7599		
	67	ALBERTS et al., "The Cell Nucleus," Chapter 8, Molecular Biology of the Cell," 1994, 3rd Edition, Garland Publishing, Inc., New York, pgs. 335-399		
	68	ANDREASSI et al., "Aclarubicin Treatment Restores SMN Levels to Cells Derived from Type I Spinal Muscular Atrophy Patients," Hum. Mol. Genet., November 15, 2001, Vol. 10, No. 24, pgs. 2841-2849		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	6	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	69	ASHE et al., "Stem-Loop 1 of the U1 snRNP Plays a Critical Role in the Suppression of HIV-1 Polyadenylation," RNA, 2000, Vol. 6, pgs. 170-177		
	70	WILLI BANNWARTH, "Solid-Phase Synthesis of Oligodeoxynucleotides containing Phosphoramidate Internucleotide Linkages and their Specific Chemical Cleavage," Helv. Chim. Acta., 1988, Vol. 71, pgs. 1517-1527		
	71	BLENCOWE, "Exonic Splicing Enhancers: Mechanism of Action, Diversity and Role in Human Genetic Diseases," Trends Biochem Sci., March 2000, Vol. 25, pgs. 106-110		
	72	BRUZZI et al., "Enhancer-Dependent Interaction Between 5' and 3' Splice Sites in Trans," Proc. Natl. Acad. Sci. USA, July 18, 1995, Vol. 92, pgs. 7056-7059		
	73	BUSSEMAKERS et al., "DD3: A New Prostate-Specific Gene, Highly Overexpressed in Prostate Cancer," Cancer Res., December 1, 1999, Vol. 59, pgs. 5975-5979		
	74	CACERES (2001) "Regulation of Alternative Splicing in Mammalian Cells," http://www.hgu.mrc.ac.uk/Research/Chrombio/Javier/Javier.htm (last updated 31 January 2001; printed 11 June 2002)		
	75	CACERES et al., "Alternative Splicing: Multiple Control Mechanisms and Involvement in Human Disease," Trends Genet., April 2002, Vol. 18, pgs. 186-193		
	76	CARLOS et al., "A 5' Splice Site-Proximal Enhancer binds SF1 and Activates Exon Bridging of a Microexon," Mol. Cell. Biol., June 2000, Vol. 11, pgs. 3988-3995		
	77	CARTEGNI et al., "Disruption of an SF2/ASF-Dependent Exonic Splicing Enhancer in SMN2 Causes Spinal Muscular Atrophy in the Absence of SMN1," Nature Genetics, April 2002, Vol. 30, pgs. 377-384		
	78	CHANG et al., "Treatment of Spinal Muscular Atrophy by Sodium Butyrate," Natl. Acad. Sci. USA, August 14, 2001, Vol. 98, pgs. 9808-9813		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	7	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	79	CHAPPELL et al., "A 9-nt Segment of a Cellular mRNA can Function as an Internal Ribosome Entry Site (IRES) and when Present in Linked Multiple Copies Greatly Enhances IRES Activity," Proc. Natl. Acad. Sci. USA, February 15, 2000, Vol. 97, pgs. 1536-1541		
	80	COOVERT et al., "The Survival Motor Neuron Protein in Spinal Muscular Atrophy," Hum. Mol. Genet., August 1997, Vol. 6, pgs. 1205-1214		
	81	COSSTICK et al., "Solid-Phase Synthesis of Oligonucleotides Containing 3'Thiothymidine," Tetrahedron Letters, 1989, Vol. 30, pgs. 4693-4696		
	82	COTE et al., "Polypyrimidine Track-Binding Protein Binding downstream of Caspase-2 Alternative Exon 9 Represses its Inclusion," J. Biol. Chem., March 16, 2001, Vol. 276, pgs. 8535-8543		
	83	COTE et al., "Caspase-2 Pre-mRNA Alternative Splicing: Identification of an Intronic Element Containing a Decoy 3' Acceptor Site," Proc. Natl. Acad. Sci. USA, January 30, 2001, Vol. 98, pgs. 938-943		
	84	CULVER et al., "In vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," Science, June 12, 1992, Vol. 256, pgs. 1550-1552		
	85	DT CURIEL, "Adenovirus Facilitation of MOlecular Conugate-mediated Gene Transfer," Prog. Med. Virol., 1993, Vol. 40, pgs. 1-18		
	86	DE ANGELIS et al., "Chimeric snRNA Molecules Carrying Antisense Sequences Against the Splice Junctions of Exon 51 of the Dystrophin Pre-mRNA Induce Exon Skipping and Restoration of a Dystrophin Synthesis in Delta 48-50 DMD Cells," Proc. Natl. Acad. Sci., July 9, 2002, Vol. 99, pgs. 9456-9461		
	87	DEROSSI et al., "The Third Helix of the Antennapedia Homeodomain Translocates Through Biological Membranes," J. Biol. Chem., April 8, 1994, Vol. 269, pgs. 10444-10450		
	88	DEROSSI et al., "Trojan Peptides: The Penetratin System for Intracellular Delivery," Trends Cell Biol., February 1998, Vol. 8, pgs. 84-87		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	8	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	89	DUNCKLEY et al., "Modification of Splicing in the Dystrophin Gene in Cultured Mdx Muscle Cells by Antisense Oligoribonucleotides," Hum. Mol. Genet., July 1998, Vol. 7, pgs. 1083-1090		
	90	ELLIOTT et al., "Dynamic Changes in the Subnuclear Organisation of Pre-mRNA Splicing Proteins and RBM During Human Germ Cell Development," J. Cell. Sci., May 1998, Vol. 111, pgs. 1255-1265		
	91	EPERON et al., "Selection of Alternative 5' Splice Sites: Role of U1 snRNP and Models for the Antagonistic Effects of SF2/ASF and hnRNP A1," Mol. Cell. Biol., November 2000, Vol. 20, pgs. 8303-8318		
	92	EPERON et al., "Splicing of mRNA Precursors in Mammalian Cells," RNA Processing - A Practical Approach, 1994, Vol. I, Eds Higgins et al, IRL Press, Oxford, pgs. 57-101		
	93	FAIRBROTHER et al., "Predictive Identification of Exonic Splicing Enhancers in Human Genes," Science, August 9, 2002, Vol. 297, pgs. 1007-1013		
	94	FARIA et al., "Phosphoramidate Oligonucleotides as Potent Antisense Molecules in Cells and in vivo," Nat. Biotechnol., January 2001, Vol. 19, pgs. 40-44		
	95	GALDERISI et al., "Antisense Oligonucleotides as Therapeutic Agents," J. Cell Physiol., November 1999, Vol. 181, pgs. 251-257		
	96	BR GRAVELEY, "Sorting out the Complexity of SR Protein Functions," RNA, September 2000, Vol. 6, pgs. 1197-1211		
	97	GRAVELEY et al., "The Role of U2AF35 and U2AF65 in Enhancer-Dependent Splicing," RNA, June 2001, Vol. 7, pgs. 806-818		
	98	GUTH et al., "Dual Function for U2AF(35) in AG-Dependent Pre-mRNA Splicing," Mol. Cell Biol., November 2001, Vol. 21, pgs. 7673-7681		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	9	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	99	HASTINGS et al., "Pre-mRNA Splicing in the New Millennium," Curr. Opin. Cell Biol., June 2001, Vol. 13, pgs. 302-309		
	100	HERTEL et al., "The Function of Multisite Splicing Enhancers," Mol. Cell., February 1998, Vol. 1, pgs. 449-455		
	101	HWANG et al., "Base Pairing at the 5' Splice Site with U1 Small Nuclear RNA Promotes Splicing of the Upstream Intron but may be Dispensable for Slicing of the Downstream Intron," Mol. Cell Biol., June 1996, Vol. 16, pgs. 3012-3022		
	102	HWANG et al., "U1 Small Nuclear RNA-Promoted Exon Selection Requires a Minimal Distance Between the Position of U1 Binding and the 3' Splice Site Across the Exon," Mol. Cell Biol., December 1997, Vol. 17, pgs. 7099-7107		
	103	HWANG et al., "A Splicing Enhancer in the 3'-Terminal c-H-ras Exon Influences mRNA abundance and Transforming Activity," J. Virol., September 1997, Vol. 71, pgs. 6416-6426		
	104	HWANG et al., "U1 snRNA Promotes the Selection of Nearby 5' Splice Sites by U6 snRNA in Mammalian Cells," Genes Dev., February 1996, Vol. 10, pgs. 338-350		
	105	JACQUE et al., "Modulation of HIV-1 Replication by RNA Interference," Nature, July 25, 2002, Vol. 418, pgs. 435-438		
	106	JAGER et al., "Oligonucleotide N-Alkylphosphoramidates: Synthesis and Binding to Polynucleotides," Biochemistry, September 20, 1988, Vol. 27, pgs. 7237-7246		
	107	JASSIM et al., "A Mismatched-Primer Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Strategy for Rapid Screening of the Polyadenylation Signal Mutation Alpha(T-Saudi) (AATAA-->AATAAG) in the Alpha2-Globin Gene," Hemoglobin, August 1999, Vol. 23, pgs. 213-220		
	108	JIANG et al., "Regulation of Ich-1 Pre-mRNA Alternative Splicing and Apoptosis by Mammalian Splicing Factors," Proc. Natl. Acad. Sci. USA, August 4, 1998, Vol. 95, pgs. 9155-9160		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	10	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	109	KASHIMA et al., "A Negative Element in SMN2 Exon 7 Inhibits Splicing in Spinal Muscular Atrophy," Nat. Genet., August 2003, Vol. 34, pgs. 460-463		
	110	KRAWCZAK et al., "The Mutational Spectrum of Single Base-Pair Substitutions in mRNA Splice Junctions of Human Genes: Causes and Consequences," Hum. Genet., September-October 1992, Vol. 90, pgs. 41-54		
	111	KRECIC et al., "hnRNP Complexes: Compositions, Structure, and Function," Curr. Opin. Cell Biol., June 1999, Vol. 11, pgs. 363-371		
	112	KURIYAMA et al., "A Potential Approach for Gene Therapy Targeting Hepatoma Using a Liver-Specific Promoter on a Retroviral Vector," Cell Struct. Funct., December 1991, Vol. 16, pgs. 503-510		
	113	KURRECK et al., "Design of antisense Oligonucleotides Stabilized by Locked Nucleic Acids," Nucleic Acids Res., May 1, 2002, Vol. 30, pgs. 1911-1918		
	114	LAOSOMBAT et al., "Interaction of the Alpha2 Polyadenylation Signal Mutation (AATAAA-->AATA--) and Alpha0-thalassemia (--SEA), Resulting in Hb H Disease in a Thai Patient," Hemoglobin, November 2001, Vol. 25, pgs. 383-389		
	115	FD LEDLEY, "Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products," Hum. Gene Ther., September 1995, Vol. 6, pgs. 1129-1144		
	116	LEFEBVRE et al., "Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene," Cell, January 13, 1995, Vol. 80, pgs. 155-165		
	117	LEITER et al., "Inhibition of Influenza Virus Replication by Phosphorothioate Oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA, May 1990, Vol. 87, pgs. 3430-3434		
	118	LIM et al., "Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3' Splice Site Pairing," J. Biol. Chem., November 30, 2001, Vol. 276, pgs. 45476-45483		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	11	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	119	LIU et al., "A Mechanism for Exon Skipping Caused by Nonsense or Missense Mutations in BRCA1 and other Genes," Nature Genet., January 2001, Vol. 27, pgs. 55-58		
	120	LORSON et al., "A Single Nucleotide in the SMN Gene Regulates Splicing and is Responsible for Spinal Muscular Atrophy," Proc. Natl. Acad. Sci. USA, May 25, 1999, Vol. 96, pgs. 6307-6311		
	121	LU et al., "Functional Amounts of Dystrophin Produced by Skipping the mutated Exon in the MDX Dystrophic Mouse," Nat. Med., August 2003, Vol. 9, pgs. 1009-1014		
	122	MARTIN et al., "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles. An Improved Method for Liposome Targeting," J. Biol. Chem., January 10, 1982, Vol. 257, pgs. 286-288		
	123	MARTINEZ et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," Cell, September 6, 2002, Vol. 110, pgs. 563-574		
	124	MBELLA et al., "A GG Nucleotide Sequence of the 3' Untranslated Region of Amyloid Precursor Protein mRNA Plays a Key Role in the Regulation of Translation and the Binding of Proteins," Mol. Cell Biol., July 2000, Vol. 20, pgs. 4572-4579		
	125	McCULLOUGH et al., "An Intronic Splicing Enhancer Binds U1 snRNPs to Enhance Splicing and Select 5' Splice Sites," Mol. Cell Biol., December 2000, Vol. 20, pgs. 9225-9235		
	126	MILLER, et al., "Targeted Vectors for Gene Therapy," Faseb J., February 1995, Vol. 9, pgs. 190-199		
	127	MONANI et al., "A single Nucleotide Difference that Alters Splicing Patterns Distinguishes the SMA Gene SMN1 from the Copy Gene SMN2," Hum. Mol. Genet., July 1999, Vol. 8, pgs. 117-1183		
	128	NASSANDER et al., "In vivo Targeting of OV-TL 3 Immunoliposomes to Ascitic Ovarian Carcinoma Cells (OVCAR-3) in Athymic Nude Mice," Cancer Res., February 1, 1992, Vol. 52, pgs. 646-653		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	12	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	129	NIELSEN et al., "Synthesis and Characterization of Dinucleoside Phosphorodithioates," Tetrahedron Letters, 1988, Vol. 29, No. 24, pgs. 2911-2914		
	130	OMIM Database Entry No. 141900 for "Hemoglobin-Beta Locus; HBB," pgs. 1-206		
	131	OMIM Database Entry No. 310200 for "Muscular Dystrophy, Duchenne Type; DMD," pgs. 1-33		
	132	RAFAEL et al., "Skeletal Muscle-Specific Expression of a Utrophin Transgene Rescues Utrophin-Dystrophin Deficient Mice," Nat. Genet., May 1998, Vol. 19, pgs. 79-82		
	133	SARIN et al., "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," Proc. Natl. Acad. Sci. USA, October 1988, Vol. 85, pgs. 7448-7451		
	134	SHAW et al., "Modified Deoxyoligonucleotides Stable to Exonuclease Degradation in Serum," Nucleic Acids Res., February 25, 1991, Vol. 19, pgs. 747-750		
	135	SHIGA et al., "Disruption of the Splicing Enhancer Sequence Within Exon 27 of the Dystrophin Gene by a Nonsense Mutation Induces Partial Skipping of the Exon and is Responsible for Becker Muscular Dystrophy," J. Clin. Invest., November 1, 1997, Vol. 100, pgs. 2204-2210		
	136	SMITH et al., "Alternative Pre-mRNA Splicing: the Logic of Combinatorial Control," Trends Biochem. Sci., August 2000, Vol. 25, pgs. 381-388		
	137	STICKELER et al., "The RNA Binding Protein YB-1 Binds A/C-Rich Exon Enhancers and Stimulates Splicing of the CD44 Alternative Exon v4," Embo J., July 16, 2001, Vol. 20, pgs. 3821-3830		
	138	STOSS, et al., "The STAR/GSG Family Protein rSLM-2 Regulates the Selection of Alternative Splice Sites," J. Biol. Chem., March 23, 2001, Vol. 276, pgs. 8665-8673		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/524,724
				Filing Date	October 18, 2006
				First Named Inventor	Matthew G. Dunckley
				Art Unit	1635
				Examiner Name	J. J. Zara
Sheet	13	of	13	Attorney Docket Number	E072 1050.1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	139	TACKE et al., "Human Tra2 Proteins are Sequence-Specific Activators of Pre-mRNA Splicing," Cell, April 3, 1998, Vol. 93, pgs. 139-148		
	140	TANG et al., "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity," Nucleic Acids Res., June 11, 1993, Vol. 21, pgs. 2729-2735		
	141	TINSLEY et al., "Expression of Full-Length Utrophin Prevents Muscular Dystrophy in MDX Mice," Nature Medicine, December 1998, Vol. 4, pgs. 1441-1444		
	142	TREISMAN et al., "Specific Transcription and RNA Splicing defects in Five Cloned Beta-Thalassaemia Genes," Nature, April 14, 1983, Vol. 302, pgs. 591-596		
	143	UZNANSKI et al., "Deoxyribonucleoside 3'-Phosphordiamidites as Substrates for Solid Supported Synthesis of Oligodeoxyribonucleotides and Their Phosphorothioate and DNA-Triester Analogues," Tetrahedron Letters, 1987, Vol. 28, No. 29, pgs. 3401-3404		
	144	VAN LEUSDEN et al., "Truncated Type XVII Collagen Expression in a Patient with Non-Herlitz Junctional Epidermolysis Bullosa Caused by a Homozygous Splice-Site Mutation," Lab Invest., June 2001, Vol. 81, pgs. 887-894		
	145	VENABLES et al., "T-STAR/ETOILE: A Novel Relative of SAM68 that Interacts with an RNA-Binding Protein Implicated in Spermatogenesis," Hum. Mol. Genet., June 1999, Vol. 8, pgs. 959-969		
	146	WAGNER et al., "Transferrin-Polycation Conjugates as Carriers for DNA Uptake into Cells," Proc. Natl. Acad. Sci. USA, May 1990, Vol. 87, pgs. 3410-3414		
	147	WANG et al., "Muring Caspase-11, an ICE-Interacting Protease, is Essential for the Activation of ICE," Cell, February 20, 1998, Vol. 92, pgs. 501-509		
	148	ZHU et al., "Pre-mRNA Splicing in the Absence of an SR Protein RS Domain," Genes Dev., December 15, 2000, Vol. 14, pgs. 3166-3178		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.